Track topics on Twitter Track topics that are important to you
[Updated 3:19 p.m.] The latest price tag for a gene therapy, a treatment meant to provide a long-lasting effect with a single dose, is now set. The treatment, Zynteglo, developed for the rare blood disease beta thalassemia, will cost roughly $1.8 million. Bluebird Bio (NASDAQ: BLUE), which just won approval of Zynteglo in Europe two […]
Original Article: Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood DiseaseNEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...